Chemring Group reported mixed first-half 2026 results, with sales growth offset by a fall in underlying operating profit as the British defence contractor absorbed significant spending to widen its manufacturing footprint.
Underlying operating profit for the six months fell to £24.5 million, down from £26.5 million a year earlier, which pulled the operating margin to 10.3% from 11.9%. Revenue rose 7% to £237.3 million from £221.9 million in the comparator period.
The largest deterioration in profitability occurred in the Sensors & Information division, where underlying operating profit declined to £9.6 million from £16.1 million and the divisional operating margin fell to 10.1% from 17.4%. The company attributed the contraction in that unit to business mix changes and reduced utilisation rates.
Net debt rose markedly during the half, nearly doubling to £144.5 million from £89.0 million at the October 2025 year-end. The increase in leverage followed capital expenditure of £44 million in the period, which Chemring said was directed at expanding energetics manufacturing capacity across sites in Chicago, Scotland and Norway.
Chemring expects those capacity investments to contribute around £30 million per annum to operating profit beginning in 2028. On the investments, chief executive Michael Ord said the energetics expansion programme was "progressing at pace, with Chicago complete and ramping production, Scotland progressing through commissioning, and Norway advancing through its next phase." The company indicated the Chicago facility is complete and in a ramp-up phase, while Scotland and Norway are at later commissioning and development stages, respectively.
Operationally, the Countermeasures & Energetics segment - the larger of the company segment delivered underlying operating profit of £26.1 million, up 31.8% year-on-year, on revenue of £142.1 million.
The company took an £8.3 million impairment charge after deciding to close its Alloy Surfaces Company unit in the United States. The closure followed a strategic review that concluded the unit could not secure sufficient orders to maintain operations.
On orders and future revenue visibility, Chemring reported a record closing order book of £1.40 billion at 30 April 2026, an 8% increase from £1.30 billion a year earlier. The firm said that 91% of expected full-year 2026 revenue was already covered by orders at that point.
Shareholders will receive a slightly higher interim dividend, with the board declaring 2.8 pence per share - up 4% from 2.7 pence in the prior interim payout. Management left full-year expectations unchanged despite the H1 profit decline and higher leverage related to the expansion programme.
Contextual note - The results show sales momentum and order book strength alongside near-term margin pressure and higher net debt owing to capacity investments targeted to lift future operating profit from 2028.